Marco de Morpurgo

Partner

GLOBAL CO-CHAIR, LIFE SCIENCES SECTOR

marco.demorpurgo@dlapiper.com

Rome
T: +39 06 68 880 1
F: +39 06 68 880 201

Marco de Morpurgo focuses on government regulation of the Life Sciences industry. He helps companies doing business in the EU navigate the complex regulatory structures governing the sector, counseling such clients on regulatory strategies and compliance matters.

He has extensive experience in the EU and national regulatory law and practice. Most of his work is multi-jurisdictional and he has broad experience assisting clients manage regulatory divergence within the EU and globally.

Marco's practice covers the regulation of pharmaceuticals, biotechnologies, medical devices, food and beverages, and other health-related regulated products. He provides strategic advice on a broad range of regulatory issues, including clinical trials, product approvals, market access, promotion and advertising, post-market obligations, as well as on anti-corruption laws and industry-specific ethical and behavioral rules. He also provides regulatory support in Life Sciences transactions and intellectual property litigation.

He regularly speaks and writes on Life Sciences topics and has been an external professor at HEC Paris.

RELATED SERVICES

- Intellectual Property and Technology

RELATED SECTORS

- Life Sciences

LANGUAGES SPOKEN

Italian English French Spanish

LANGUAGES SPOKEN

- Italian
- English
- French
- Spanish

VITA

Zulassung

- Avvocato admitted to the Rome Bar
- Avocat admitted to the Paris Bar
- Abogado registered with Ilustre Colegio de Abogados de Madrid
- Attorney-at-Law zugelassen beim Supreme Court von New York

Berufserfahrung

- Before joining DLA Piper, Marco worked with leading international law firms in Brussels, London and Paris.

Ausbildung

- University of Milan, Ph.D., Comparative Law
- Harvard Law School, LL.M.
- IUC Turin, M.Sc., Comparative Law, Economics & Finance
- University of Trieste, Law degree

AKTUELLES

Veröffentlichungen

- EU SPC Manufacturing Waiver Becomes Effective: What Can Industry Expect?, European Pharmaceutical Law Review, Volume 3, Issue 3 (2019)
- The Sun Also Rises in Italy: New Statutory Transparency Requirements Expected under the Proposed Italian Sunshine Act, European Pharmaceutical Law Review, Volume 2, Issue 4 (2018)
- Italy Reforms Clinical Trial Rules, European Pharmaceutical Law Review, Volume 2, Issue 1 (2018)

NEWS

DLA Piper launches global cannabis practice

21 February 2020

DLA Piper has launched a dedicated global cannabis practice that will sit as a sub-group under its Life Sciences sector. The decision to formalise the firm's offering follows the completion of a significant number of global deals in the sector that have amounted to over USD8 billion to date, as well as a number of large cannabis regulatory advisory mandates.